

Datasheet for BSA-30-0050**Bovine Serum Albumin 30% Solution****Overview**

Description:	Bovine Serum Albumin 30% Solution - BSA-30-0050
Item No.:	BSA-30-0050
Size:	50 mL
Applications:	Biochemical Assay, ELISA, Other
Origin:	Bovine

Product Details

Background:	Bovine Serum Albumin (BSA) is used for various biochemical applications including ELISA (Enzyme-Linked Immunosorbent Assay), high content screening assays, western blotting, and immunohistochemistry. BSA as a blocking reagent is particularly useful with casein-sensitive antibodies, such as phospho-specific antibodies. Sterile validated preparations may be used as a nutrient in cell and microbial culture. In restriction digests, specially prepared BSA is used to stabilize some enzymes during digestion of DNA and to prevent adhesion of the enzyme to reaction tubes and other vessels. Bovine Serum Albumin can also be used to determine the quantity of other proteins, by comparing an unknown quantity of protein to known amounts of BSA.
Synonyms:	BOVINE SERUM ALBUMIN, BSA, BSA Blocker, BSA Blocking, BSA30
Species of Origin:	Bovine

Target Details

Purity/Specificity:	BOVINE SERUM ALBUMIN 30% Solution contains a 30% solution of bovine serum albumin (Fraction V, Immunoglobulin and Protease Free) in saline with preservative and stabilizer. The product is ~30% protein as determined by Biuret assay. A clear yellow green to dark amber color is typical. This product is prepared from healthy adult animals and is processed from pooled lots of serum to ensure uniformity.
Relevant Links:	• BSA-30 SDS

Application Details

Suggested Applications:	Biochemical Assay, ELISA, Other (Based on references)
Application Note:	BOVINE SERUM ALBUMIN 30% Solution is suitable for use in protease sensitive assays such as RIA, EIA and nucleic acid hybridization, use as a stabilizing agent for proteins and enzymes, including dilute solutions of antibody, and use as a blocking agent to reduce non-specific binding.
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.
ELISA:	User Optimized
FLISA:	User Optimized
IF:	User Optimized
IHC:	User Optimized
IP:	User Optimized
WB:	User Optimized


Formulation

Physical State:	Liquid (sterile filtered)
Concentration:	30 % by dry weight
Buffer:	0.85% (w/v) Sodium Chloride
Preservative:	0.01% (w/v) Sodium Azide
Stabilizer:	0.3% (v/v) Octanoic Acid

Shipping & Handling

Shipping Condition:	Wet Ice
Storage Condition:	Store Blocking Buffer at 4° C prior to opening. DO NOT FREEZE.
Expiration:	Expiration date is six (6) months from date of receipt.

Images




Immunofluorescence Microscopy

Internalization of basigin monoclonal antibodies (mAbs) in hCMEC/D3 cells. (a) Representative confocal images of selected basigin mAbs exposed to hCMEC/D3 cells for 10 and 30 min. Basigin mAbs in green and nuclei visualized by Hoechst in blue. The pictures are the maximum projection of the z-stack, and the XZ projection is below the pictures. Scale bar 30 μ m. (b) Quantification of intracellular spots using Cellomics Arrayscan after acid stripping and staining. The intensities are normalized to the negative control and plotted as the percentage increase in spot intensity per cell with $\pm$ standard error of the mean (SEM). Secondary antibody diluted in PBS with 2% BSA (p/n BSA-30). Figure 6. PMID: 32884039.

Surface Plasmon Resonance (SPR)

Surface plasmon resonance sensorgrams representing the binding of basigin extracellular domain to captured anti-basigin monoclonal antibodies. The fitted curves used for equilibrium dissociation constant (KD) calculations were obtained using the Langmuir 1:1 binding model in the Biacore S200 evaluation software and plotted in GraphPad Prism (colored in black). (a) bin A, (b) bin D, (c) bin AD, (d) bin B, and (e) bin C. At the end of each cycle, the sensor surface was regenerated in 3 M MgCl₂ for 30 s. 1 $\times$ HBS-P + with 1 mg/ml bovine serum albumin (BSA, p/n BSA-30) was used as running buffer for the kinetic analyses. mAb monoclonal antibody, RU response unit. Figure 3. PMID: 32884039.



Bottle

Bovine Serum Albumin 30% Solution

References

- Bader DLV et al. Structural and immunogenetic signatures guide CD4-mimetic HIV vaccine development. *Cell Rep.* (2026)
- Steichen JM et al. Vaccination elicits HIV broadly neutralizing antibodies in primates. *Nature.* (2026)
- Shan X et al. Protocol for generating NGN2 iPSC lines and large-scale human neuron production. *STAR Protoc.* (2025)
- McKinnon Walsh R et al. Depletion of tumor-derived CXCL5 improves T cell infiltration and anti-PD-1 therapy response in an obese model of pancreatic cancer. *J Immunother Cancer.* (2025)
- Chung HS et al. Therapeutic potential of phytochemical luteolin in restoring skin barrier by inhibiting antimicrobial peptides associated with TRAF6/TAK1/IKK/I κ B in psoriasis-like HaCaT models. *Food Sci Biotechnol.* (2025)
- Saito Y et al. Enhancing cancer cell immunocapture on orientation-controlled nanoimprinted microcone arrays in microgap channels. *Lab Chip.* (2025)
- Mehrotra S et al. Pharmacological Characterization of Zasocitinib (TAK-279): An Oral, Highly Selective, and Potent Allosteric TYK2 Inhibitor. *J Invest Dermatol.* (2025)
- Jarvi NL et al. Immune regulatory adjuvant approach to mitigate subcutaneous immunogenicity of monoclonal antibodies. *Front Immunol.* (2024)
- Yang X et al. Qualitative immunoassay for the detection of anti-SARS-COV-2 spike antibody in human milk samples. *STAR Protoc.* (2022)
- Christensen SC et al. Characterization of basigin monoclonal antibodies for receptor-mediated drug delivery to the brain. *Sci Rep.* (2020)
- Ferdman J et al. Intra-seasonal antibody repertoire analysis of a subject immunized with an MF59[®]-adjuvanted pandemic 2009 H1N1 vaccine. *Vaccine.* (2019)
- Raymond DD et al. Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain. *Nat Med.* (2016)
- Schmidt AG et al. Viral receptor-binding site antibodies with diverse germline origins. *Cell.* (2015)
- Keeler, GD et al. Comparison of microdialysis sampling perfusion fluid components on the foreign body reaction in rat subcutaneous tissue. *European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences* (2014)

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.